|Country:||Switzerland and USA|
|Category:||Clinical Stage Biotech Company|
|Date:||April 24, 2023|
|Time:||15:30 – 15:45|
|Speaker:||Dr. Theresa Visarius, Managing Director Immunophotonics Switzerland (IPS Biopharma AG)|
Immunophotonics, Inc. is a privately owned clinical stage biotech that provides an innovative solution to combat solid metastatic cancers. The company is in phase 2 multi-indication clinical development of IP-001, an immune-stimulating drug designed to induce tumor-specific, potent antitumor immune activation. Early clinical data show shrinkage of both treated tumors and distant metastases. IP-001 is the first asset in clinical development from broad intellectual property.